Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration
- 31 July 1993
- journal article
- Published by Elsevier BV in American Heart Journal
- Vol. 126 (1), 11-14
- https://doi.org/10.1016/s0002-8703(07)80004-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice?New England Journal of Medicine, 1992
- Adjunctive use of beta-adrenergic blockers, calcium antagonists and other therapies in coronary thrombolysisThe American Journal of Cardiology, 1991
- Verapamil inhibits serotonin uptake of endothelial cells in culture by a mechanism unrelated to Ca2+ channel blockadeJournal of Cellular Physiology, 1987
- Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndromeThe American Journal of Cardiology, 1987
- Effects of nifedipine on platelet functionAmerican Heart Journal, 1985
- Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.Circulation, 1985
- Verapamil, an antagonist at 5-Hydroxytryptamine receptors of human blood plateletsEuropean Journal of Pharmacology, 1985
- Effects of oral diltiazem in paroxysmal supraventricular tachycardiaThe American Journal of Cardiology, 1983
- Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogsThe American Journal of Cardiology, 1983
- Interaction of calcium antagonists with cyclic AMP phosphodiesterases and calmodulinBiochemical and Biophysical Research Communications, 1982